EU/3/18/2082

About

On 19 November 2018, orphan designation (EU/3/18/2082) was granted by the European Commission to Takeda Pharma A/S, Denmark, for 5-{(1R,2R)-2-[(cyclopropylmethyl)amino]cyclopropyl}-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide monohydrochloride (also known as TAK-418) for the treatment of Kabuki syndrome.

The sponsor’s address was updated in August 2020.

Key facts

Active substance
5-{(1R,2R)-2-[(cyclopropylmethyl)amino]cyclopropyl}-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide monohydrochloride
Disease / condition
Treatment of Kabuki syndrome
Date of first decision
19/11/2018
Outcome
Positive
EU designation number
EU/3/18/2082

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Takeda Pharma A/S
Delta Park 45
2665 Vallensbaek Strand
Hovedstaden
Danmark
Tel: +45 4677 1111
E-mail: kristina.stovring@takeda.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating